Applied Filters
Fed Circ affirms Eli Lilly victories over cancer drugs
The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.
Akebia Therapeutics and Par Pharma settle Auryxia suit
A subsidiary of Akebia Therapeutics has entered into a settlement agreement with Endo-owned Par Pharmaceutical.
Allergan to pay $2.7m to settle antitrust suit over Asacol
A subsidiary of Irish pharmaceutical company Allergan is to pay a combined total of $2.7 million to three organisations that were part of an antitrust class against the drugmaker.
Bausch Health resolves IP litigation with Teva
Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Alkermes settles with Amneal over opioid dependence treatment
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.
Teva to pay California $69m over pay-for-delay deals
The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.
Pfizer off-patent division to merge with Mylan
Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.
Celgene settles antitrust class-action for $55m
US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
FDA opens US to Lyrica generics
The US Food and Drug Administration last week approved nine applications for the first generic versions of Pfizer’s Lyrica.
Endo pays $2.3m to settle states antitrust claims
Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
